Targeted therapy is a groundbreaking innovation for cancer treatment. Among the receptor
tyrosine kinases, the fibroblast growth factor receptors (FGFRs) garnered substantial …

Simple Summary Deregulation of the FGF/FGFR axis is associated with many types of
cancer and contributes to the development of chemoresistance, limiting the effectiveness of …

Fibroblast growth factor receptors (FGFRs) are implicated in a range of cancers with several
pan-kinase and selective-FGFR inhibitors currently being evaluated in clinical trials. Pan …

Background Neuroblastoma is a devastating disease accounting for 15% of all childhood
cancer deaths. Yet, our understanding of key molecular drivers such as receptor tyrosine …

Simple Summary Ovarian cancer is the most lethal gynecological cancer. Currently there is
no curative treatment for relapsed, standard treatment resistant ovarian cancer. Here we …

Ovarian cancer is a deadly gynecologic cancer, and the majority of patients with ovarian
cancer experience relapse after traditional treatment. Cisplatin (DDP) is a common …

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are
involved in the regulation of cell proliferation, survival, and development. FGFR alterations …

For advanced cancers of the digestive system, personalized, precise treatment can be life
saving. With the development of next-generation sequencing technology, detection of fusion …

Alofanib is a small-molecule allosteric extracellular FGFR2 inhibitor. We report safety and
preliminary efficacy from the first-in-human phase 1b study of alofanib in heavily pretreated …

Ovarian cancer is one of the most common malignant tumors in women, and treatment
options are limited. Despite efforts to adjust cancer treatment models and develop new …